PMID- 20723849
OWN - NLM
STAT- MEDLINE
DCOM- 20101213
LR  - 20181201
IS  - 1876-7605 (Electronic)
IS  - 1936-8798 (Linking)
VI  - 3
IP  - 8
DP  - 2010 Aug
TI  - Impact of bivalirudin therapy in high-risk patients with acute myocardial 
      infarction: 1-year results from the HORIZONS-AMI (Harmonizing Outcomes with 
      RevasculariZatiON and Stents in Acute Myocardial Infarction) trial.
PG  - 796-802
LID - 10.1016/j.jcin.2010.05.009 [doi]
AB  - OBJECTIVES: This study sought to assess the relationship between 1-year mortality 
      and baseline patient risk in the HORIZONS-AMI (Harmonizing Outcomes with 
      RevasculariZatiON and Stents in Acute Myocardial Infarction) trial. BACKGROUND: 
      The HORIZONS-AMI trial showed that bivalirudin compared with unfractionated 
      heparin (UFH) plus glycoprotein IIb/IIIa inhibitors (GPI) decreased major 
      bleeding and 30-day and 1-year mortality in patients undergoing primary 
      percutaneous intervention for acute myocardial infarction. METHODS: Patients in 
      the HORIZONS-AMI trial were classified as low, intermediate, and high risk 
      according to the CADILLAC (Controlled Abciximab and Device Investigation to Lower 
      Late Angioplasty Complications) risk score based on 7 clinical variables. 
      RESULTS: Among 2,530 CADILLAC-score evaluable HORIZONS-AMI trial patients, 1,522 
      (60%) were classified as low risk, 531 (21%) as intermediate risk, and 477 (19%) 
      as high risk. The mortality rates in the bivalirudin and UFH plus GPI arms, 
      respectively, were 0.4% and 1.2% (p = 0.09) in the low-risk group, 4.2% and 4.1% 
      (p = 0.99) in the intermediate-risk group, and 8.4% and 15.9% (p = 0.01) in the 
      high-risk group. Among high-risk patients, there was also a decreased rate of 
      recurrent myocardial infarction in patients randomized to bivalirudin as compared 
      to UFH plus GPI (3.6% vs. 7.9%, p = 0.04). CONCLUSIONS: In high-risk patients 
      undergoing primary percutaneous coronary intervention for acute myocardial 
      infarction, bivalirudin compared with UFH plus GPI reduces 1-year mortality and 
      recurrent myocardial infarction. (HORIZONS-AMI trial; NCT00433966).
CI  - Copyright (c) 2010 American College of Cardiology Foundation. Published by 
      Elsevier Inc. All rights reserved.
FAU - Parodi, Guido
AU  - Parodi G
AD  - Division of Cardiology Careggi Hospital, Florence, Italy.
FAU - Antoniucci, David
AU  - Antoniucci D
FAU - Nikolsky, Eugenia
AU  - Nikolsky E
FAU - Witzenbichler, Bernhard
AU  - Witzenbichler B
FAU - Guagliumi, Giulio
AU  - Guagliumi G
FAU - Peruga, Jan Z
AU  - Peruga JZ
FAU - Stuckey, Thomas
AU  - Stuckey T
FAU - Dudek, Darius
AU  - Dudek D
FAU - Kornowski, Ran
AU  - Kornowski R
FAU - Hartmann, Franz
AU  - Hartmann F
FAU - Lansky, Alexandra J
AU  - Lansky AJ
FAU - Mehran, Roxana
AU  - Mehran R
FAU - Stone, Gregg W
AU  - Stone GW
LA  - eng
SI  - ClinicalTrials.gov/NCT00433966
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - JACC Cardiovasc Interv
JT  - JACC. Cardiovascular interventions
JID - 101467004
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antithrombins)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Hirudins)
RN  - 0 (Immunoglobulin Fab Fragments)
RN  - 0 (Peptide Fragments)
RN  - 0 (Peptides)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Recombinant Proteins)
RN  - 9005-49-6 (Heparin)
RN  - NA8320J834 (Eptifibatide)
RN  - TN9BEX005G (bivalirudin)
RN  - X85G7936GV (Abciximab)
SB  - IM
CIN - JACC Cardiovasc Interv. 2010 Aug;3(8):803-5. PMID: 20723850
MH  - Abciximab
MH  - Aged
MH  - Angioplasty, Balloon, Coronary/adverse effects/*instrumentation/mortality
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Antithrombins/adverse effects/*therapeutic use
MH  - Chi-Square Distribution
MH  - Eptifibatide
MH  - Europe
MH  - Female
MH  - Fibrinolytic Agents/adverse effects/*therapeutic use
MH  - Hemorrhage/chemically induced
MH  - Heparin/therapeutic use
MH  - Hirudins/adverse effects
MH  - Humans
MH  - Immunoglobulin Fab Fragments/therapeutic use
MH  - Israel
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/drug therapy/mortality/*therapy
MH  - Patient Selection
MH  - Peptide Fragments/adverse effects/*therapeutic use
MH  - Peptides/therapeutic use
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Prospective Studies
MH  - Recombinant Proteins/adverse effects/therapeutic use
MH  - Risk Assessment
MH  - Risk Factors
MH  - Secondary Prevention
MH  - *Stents
MH  - Time Factors
MH  - Treatment Outcome
MH  - United States
EDAT- 2010/08/21 06:00
MHDA- 2010/12/14 06:00
CRDT- 2010/08/21 06:00
PHST- 2010/04/27 00:00 [received]
PHST- 2010/05/20 00:00 [revised]
PHST- 2010/05/31 00:00 [accepted]
PHST- 2010/08/21 06:00 [entrez]
PHST- 2010/08/21 06:00 [pubmed]
PHST- 2010/12/14 06:00 [medline]
AID - S1936-8798(10)00379-1 [pii]
AID - 10.1016/j.jcin.2010.05.009 [doi]
PST - ppublish
SO  - JACC Cardiovasc Interv. 2010 Aug;3(8):796-802. doi: 10.1016/j.jcin.2010.05.009.